280 related articles for article (PubMed ID: 19363055)
1. Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era.
Kai F; Takayama T; Sugiyama T; Furuse H; Mugiya S; Ozono S
Jpn J Clin Oncol; 2009 May; 39(5):310-4. PubMed ID: 19363055
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control.
Basting R; Corvin S; Händel D; Hinke A; Schmidt D
Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142
[TBL] [Abstract][Full Text] [Related]
5. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): prognostic value of DNA cytophotometry.
Basting R; Corvin S; Händel D; Hinke A; Schmidt D
Anticancer Res; 1999; 19(2C):1493-5. PubMed ID: 10365130
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
[TBL] [Abstract][Full Text] [Related]
11. [Influential clinical and pathological factors on prognosis of renal cell carcinoma].
Saika T; Yamamoto Y; Takeda K; Asahi T
Hinyokika Kiyo; 1994 Mar; 40(3):189-93. PubMed ID: 7513936
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of renal cell carcinoma with extension into inferior vena cava.
Tanaka M; Fujimoto K; Okajima E; Tanaka N; Yoshida K; Hirao Y
Int J Urol; 2008 May; 15(5):394-8. PubMed ID: 18452454
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of renal cell carcinoma with interferons].
Oya M
Nihon Rinsho; 2006 Jul; 64(7):1281-5. PubMed ID: 16838645
[TBL] [Abstract][Full Text] [Related]
14. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
15. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
[TBL] [Abstract][Full Text] [Related]
16. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.
Klatte T; Patard JJ; Wunderlich H; Goel RH; Lam JS; Junker K; Schubert J; Böhm M; Allhoff EP; Kabbinavar FF; Crepel M; Cindolo L; De La Taille A; Tostain J; Mejean A; Soulie M; Bellec L; Bernhard JC; Ferriere JM; Pfister C; Albouy B; Colombel M; Zisman A; Belldegrun AS; Pantuck AJ
J Urol; 2007 Jun; 177(6):2081-6; discussion 2086-7. PubMed ID: 17509291
[TBL] [Abstract][Full Text] [Related]
17. Outcome of nephron-sparing surgery for T1b renal cell carcinoma.
Joniau S; Vander Eeckt K; Srirangam SJ; Van Poppel H
BJU Int; 2009 May; 103(10):1344-8. PubMed ID: 19040528
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for survival of patients after curative surgery for renal cell carcinoma: multivariate analysis of 482 cases.
Uno M; Fujimoto Y; Takada T; Ishida K; Kubota Y; Katoh S; Hagiwara N; Minamidate Y; Yokoi S; Deguchi T;
Int J Clin Oncol; 2004 Dec; 9(6):510-4. PubMed ID: 15616883
[TBL] [Abstract][Full Text] [Related]
19. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
[TBL] [Abstract][Full Text] [Related]
20. Our experience with interferon alpha: renal cell carcinoma.
Merimsky O; Chaitchik S
Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
